| Literature DB >> 32458649 |
Natsuda Aumpan1,2, Ratha-Korn Vilaichone1,2,3, Pornpen Gamnarai2,4, Likhasit Sanglutong1, Thawee Ratanachu-Ek5, Varocha Mahachai2,6, Yoshio Yamaoka7.
Abstract
BACKGROUND: Gastric cancer, which is the leading cause of cancer mortality in Cambodia, can be prevented by Helicobacter pylori (H. pylori) eradication. There is limited data about H. pylori strains in Cambodia. This study aimed to evaluate H. pylori prevalence and antibiotic resistance in Koh Kong, Cambodia.Entities:
Keywords: Antibiotic Resistance; Cambodia; Helicobacter pylori
Mesh:
Substances:
Year: 2020 PMID: 32458649 PMCID: PMC7541852 DOI: 10.31557/APJCP.2020.21.5.1409
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Demographic Data, Comorbidities and Endoscopic Findings between Groups
| Groups | Total |
|
|
|
|---|---|---|---|---|
| Number of patients | 58 (100%) | 18 (31.0%) | 40 (69.0%) | - |
| Gender | 0.386 | |||
| Male | 18 (31.0%) | 7 (38.9%) | 11 (27.5%) | |
| Female | 40 (69.0%) | 11 (61.1%) | 29 (72.5%) | |
| Mean age ± SD (yr) | 43.8 ± 12.2 | 46.8 ± 11.2 | 42.4 ± 12.5 | 0.202 |
| Range | 15 - 62 | 20 - 62 | 15 - 61 | |
| Comorbidities | ||||
| None | 47 (81.0%) | 14 (77.8%) | 33 (82.5%) | 0.724 |
| Hypertension | 8 (13.8%) | 2 (11.1%) | 6 (15.0%) | 1.000 |
| Diabetes mellitus | 2 (3.4%) | 1 (5.6%) | 1 (2.5%) | 0.528 |
| Median duration of symptoms (months) | 36 | 42 | 36 | 0.680 |
| IQR | 12 - 75 | 15 - 111 | 12 - 69 | |
| Endoscopic findings | 0.641 | |||
| Gastritis | 53 (91.4%) | 16 (88.9%) | 37 (92.5%) | |
| Peptic ulcer diseases | 5 (8.6%) | 2 (11.1%) | 3 (7.5%) |
Prevalence of Antibiotic-Resistant H. pylori Strains
|
| Number of patients (%) |
|---|---|
| No antibiotic resistance | 7.1 |
| Antibiotic resistance | |
| Amoxicillin (AMX) | 0 |
| Tetracycline (TET) | 0 |
| Clarithromycin (CLR) | 27.8 |
| Metronidazole (MNZ) | 78.6 |
| Ciprofloxacin (CIP) | 50.0 |
| Levofloxacin (LVX) | 50.0 |
| >1 antibiotic resistance | |
| CLR and MNZ | 7.1 |
| MNZ, CIP, and LVX | 35.7 |
| CLR, MNZ, CIP, and LVX | 14.3 |
*(n = 14)
CYP2C19 Genotype
| CYP2C19 genotype | Number of patients (%) |
|---|---|
| Rapid metabolizer | 10 (55.6) |
| Intermediate metabolizer | 7 (38.9) |
| Poor metabolizer | 1 (5.5) |
*(n = 18)